Benefit of Vanadium Compound in Therapy for Cardiovascular Diseases

DOI Web Site Web Site PubMed 25 References
  • Fukunaga Kohji
    Department of Pharmacology, Graduate School of Pharmaceutical Sciences, Tohoku University

Bibliographic Information

Other Title
  • 心血管障害治療におけるバナジウム化合物の有用性
  • シンケツカン ショウガイ チリョウ ニ オケル バナジウム カゴウブツ ノ ユウヨウセイ

Search this article

Abstract

  There is an increase in cardiovascular disease and cardiovascular risk after menopause. Development of animal models of cardiovascular disease in postmenopause is critical to define pathophysiological mechanism underlying cardiovascular injury and to advance in the therapy. We first developed a rat model of postmenopausal cardiac myocardial hypertrophy and dysfunction. Rats were surgically ovariectomized (OVX) and subjected to pressure overload (PO) by aortic banding. We found marked reduction of protein kinase B (Akt) activity and endothelial nitric oxide synthase (eNOS) phosphorylation. Since we found bis(1-oxy-2-pyridinethiolato) oxovanadium (IV) (VO(OPT)), as strong stimulator of Akt in vivo, we treated it for OVX-PO hypertrophy model. Interestingly, VO(OPT) treatment significantly attenuated cardiac hypertrophy and prevented the progress from hypertrophy to heart failure. The cardioprotective effects of VO(OPT) were closely associated with increases in Akt activity and eNOS phosphorylation in the left ventricule. The cardiac hypertrophy and contractile dysfunction were significantly improved by VO(OPT) treatment. Taken together vanadium compound are possible therapeutics for cardiac hypertrophy and heart failure following hypertension in postmenopausal women.<br>

Journal

  • YAKUGAKU ZASSHI

    YAKUGAKU ZASSHI 132 (3), 279-284, 2012-03-01

    The Pharmaceutical Society of Japan

References(25)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top